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Abstract
Matrix metalloproteinases have been traditionally linked to
cancer dissemination through their ability to degrade most
extracellular matrix components, thus facilitating invasion
and metastasis of tumor cells. However, recent functional
studies have revealed that some metalloproteases, including
several members of the ADAMTS family, also exhibit tumor
suppressor properties. In particular, ADAMTS1, ADAMTS9, and
ADAMTS18 have been found to be epigenetically silenced in
malignant tumors of different sources, suggesting that they
may function as tumor suppressor genes. Herein, we show that
ADAMTS15 is genetically inactivated in colon cancer. We have
performed a mutational analysis of the ADAMTS15 gene in
human colorectal carcinomas, with the finding of four
mutations in 50 primary tumors and 6 colorectal cancer cell
lines. Moreover, functional in vitro and in vivo studies using
HCT-116 and SW-620 colorectal cancer cells and severe
combined immunodeficient mice have revealed that
ADAMTS15 restrains tumor growth and invasion. Further-
more, the presence of ADAMTS15 in human colorectal cancer
samples showed a negative correlation with the histopatho-
logic differentiation grade of the corresponding tumors.
Collectively, these results provide evidence that extracellular
proteases, including ADAMTS15, may be targets of inactivat-
ing mutations in human cancer and further validate the
concept that secreted metalloproteases may show tumor
suppressor properties. [Cancer Res 2009;69(11):4926–34]
Introduction
The establishment of causal relationships between proteolytic
activities and tumor progression has prompted to consider
proteases as suitable targets for anticancer therapy (1–5). However,
an increasing body of evidence indicates that some proteases can
confer antitumorigenic properties (6, 7). Among them, there are
several members of the a disintegrin and metalloproteinase with
thrombospondin domains (ADAMTS) family including ADAMTS1,
ADAMTS8, ADAMTS9, ADAMTS12, ADAMTS15, and ADAMTS18
(7). All of them share a complex structural design characterized by
the presence of a metalloproteinase domain linked to a variety of
specialized ancillary domains including a series of thrombospondin-
1 repeats (8–11). ADAMTS are secreted enzymes, which, on secre-
tion, remain located at the pericellular space through interactions
of their thrombospondin-1 motifs and spacer regions with ex-
tracellular matrix components (11, 12). Several reports have shown
that the tumor suppressor activities of ADAMTS1 and ADAMTS8
derive from the angio-inhibitory capacities of their thrombospon-
din-1 domains (13, 14), whereas ADAMTS12 inhibits tumor growth
through its ability to modulate the Ras-dependent extracellular
signal-regulated kinase (ERK) signaling pathway (15). In addition to
these biochemical studies, genetic and epigenetic analyses have
supported the proposal that ADAMTS family members may act as
antitumor proteases. Thus, ADAMTS1, ADAMTS9 , and ADAMTS18
have been identified as epigenetically silenced genes in several
carcinomas (16–18). The putative role of ADAMTS15 as a potential
tumor-protective protease has recently emerged after the finding
that its overexpression is a sign of favorable outcome in breast
cancer patients (19). Furthermore, mutational analysis of most
protein coding genes in a small set of human breast and colorectal
carcinomas has revealed the occurrence of some mutations in
ADAMTS15 (20, 21). However, no functional studies have been done
to evaluate the potential consequences of these mutations in
tumor development and progression.
In this work, we have investigated the potential role of
ADAMTS15 as a candidate tumor suppressor protease through
an exhaustive analysis of both ADAMTS15 genetic and epigenetic
alterations in a large collection of human colorectal carcinomas.
We have also performed a series of functional analyses to assess the
protective nature of ADAMTS15, with the finding that depletion of
this protease markedly promotes in vitro and in vivo tumor growth
and invasion, whereas overexpression of the enzyme reverses the
phenotype. Finally, data obtained from human tissue microarrays
show a negative correlation between ADAMTS15 expression and
differentiation grade of colon carcinomas. Overall, our data indi-
cate that ADAMTS15 is a metalloprotease with tumor suppressor
properties.
Materials and Methods
Mutational analysis. Genomic DNA from a set of 50 normal/tumor
paired colorectal tissue samples were obtained from patients subjected to
surgery at Institut Catala` d’Oncologia. PCR amplification of ADAMTS15
coding exons was done as described by Sjoblom et al. (20). Sequence data
were analyzed using Mutation Surveyor software (20). Both tumor and
normal paired tissue samples were resequenced to validate potential
mutations and discard germ-line variants. Potential effect of an amino acid
change in the ADAMTS15 protein function was predicted in silico using the
Sorting Intolerant From Tolerant algorithm (22). This computational Web-
based approach calculates a score, ranging from 0 to 1, which corresponds
to the probability that a particular change in an amino acid is tolerated.
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This software uses alignments among the members of one family to predict
if an amino acid is essential for the function of the protein.
cDNA constructs. ADAMTS15 full-length human cDNA (23) was
subcloned in pcDNA3.1 expression vector. The same cDNA was employed
to delete a guanine at position 2547 (pcDNA-ADAMTS15DG2547 vector;
ADAMTS15_G849fs protein). To this end, cassette mutagenesis was carried
out by overlap extension (24) using the following primers: TS15bamFOR
5¶-CCAAATGGGATCCCTATGGCC-3¶, TS15REV 5¶-CGCGGAGCACGGCCC-
CAGCTGCCAGCCAC-3¶, TS15FOR 5¶-GCAGCTGGGGCCGTGCTCCGC-
GAGCTGCGG-3¶, and TS15hindREV 5¶-AAGCTTGCACGGCCTCAGGAC-3¶.
An additional construct was generated using a modified pCEP4 expression
vector and a FLAG epitope at the COOH-terminal region of the protein.
Cell culture and transfection. Colorectal tumor cell lines HCT-116, SW-
480, SW-620, LoVo, DLD-1, and Caco-2 were purchased from the American
Type Culture Collection. Cells were routinely maintained in DMEM, with
the exception of SW-620 cells that were grown in L-15 medium. Cells were
transfected with the Lipofectamine reagent, and stable clones were selected
in the presence of 2 Ag/mL puromycin.
DNA methylation analysis and reverse transcription-PCR analysis.
Methyl Primer Express version 1.0 software (Applied Biosystems) was used
to identify CpG islands in an interval of 2.0 kb upstream and 1.5 kb
downstream from the first ATG codon. The same program was used to
design primers to amplify methylated or unmethylated DNA in both
promoter and first exon regions. To evaluate ADAMTS15 expression, cDNA
was synthesized using 1 Ag purified RNA and the ThermoScript Reverse
Transcription-PCR System (Invitrogen). To quantitatively assess ADAMTS15
expression levels in colorectal cancer cells, quantitative reverse transcription-
PCR was done using the Taqman probe Hs01054400_g1 from Applied Bio-
systems. All reactions were done in quadruplicates.
RNA interference. A panel of four ADAMTS15 specific short hairpin
RNA (shRNA; 5¶-TCTTCAGACCTGCGACGCTGCTTCTATTC-3¶, 5¶-AGA-
GAAGCTGCTCTGTCATTGAGGACGAT-3¶, 5¶-GCTACAACCACAGCAC-
CAACCGGCTCACT-3¶, and 5¶-TCTGTGTCCAAGGCAAGTGCATCAAGGCT-
3¶) introduced into the pRetroSuper (pRS) vector was purchased from
OriGene. SW-620 or 293-EBNA cells were transfected with these vectors or
with pRS control vector and selected with 1 Ag/mL puromycin.
Figure 1. Somatic mutations in ADAMTS15 gene. A , domain organization of ADAMTS15 and sequencing electropherograms obtained from paired normal/tumor
colorectal samples and cell lines. Arrowheads, positions of somatic mutations; asterisks, nonsynonymous mutations (red ), synonymous mutation (blue ), and previously
reported mutations in colorectal cancer (brown ). B , alignment of the identified mutations with ADAMTS15 orthologues from the indicated species. Sequences are fully
conserved with the exception of the indicated amino acids. Altered amino acids by somatic mutations are boxed.
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Colony formation assays. HCT-116 cells plated in 60 mm dishes were
transfected with the wild-type or mutant ADAMTS15DG2547 expression
vectors along with the corresponding control vector. Then, cells were
trypsinized, plated in 6-well dishes, and cultured in medium containing
0.4 mg/mL geneticin for 15 days. SW-620 cells were also transfected with the
interfering constructs along with the control vector as described above.
Colonies were stained with 0.5% crystal violet in 20% methanol and counted
in eight randomly selected microscopic fields.
Invasion assays. In vitro invasion potential was evaluated using
24-well Matrigel-coated invasion chambers with an 8 Am pore size (BD
Biosciences). For HCT-116, 5  104 cells were allowed to migrate for
48 h using 5% fetal bovine serum as a chemoattractant. In the case of
SW-620 cells, invasion of 1  105 cells was evaluated after 96 h using 2%
fetal bovine serum. Cells that reached the lower surface were stained
with crystal violet and counted in 10 randomly selected microscopic
fields.
Western blot. Western blot analysis was done using the following
primary antibodies: H-135 anti-ADAMTS15 (Santa Cruz Biotechnology),
anti-p44/42 mitogen-activated protein kinase, anti-phospho-p44/42 mitogen-
activated protein kinase (Cell Signaling Technology), anti-FLAG-M2 (Sigma-
Aldrich), and anti-actin (Abcam). Immunoreactive bands were visualized
using horseradish peroxidase-labeled secondary antibodies and chemilu-
minescent horseradish peroxidase substrate (Millipore). To detect recom-
binant proteins, the indicated cells were transfected with pCEP-ADAMTS15-
FLAG (15), pcDNA-ADAMTS15DG2547, or the corresponding empty vector.
Cell extracts along with the conditioned medium were used for Western
blot analysis.
Immunostaining. Two human tissue arrays with normal and tumor
colorectal samples were obtained from the Hospital Universitario Central
de Asturias and used to evaluate ADAMTS15 expression. After dewaxing and
rehydrating, samples were incubated overnight with H-135 antibody at 1:200
dilution. Sections were incubated with EnVision System-labeled polymer
horseradish peroxidase anti-rabbit (DAKO) followed by incubation with
diaminobenzidine colorimetric reagent (DAKO) and counterstaining with
hematoxylin. To detect ADAMTS15 in HCT-116 cells, immunofluorescence
was carried out as described (15).
In vivo tumorigenicity. Experimentation with severe combined
immunodeficient mice (C.B-17/IcrCrl-scid-BR; Charles River Laboratories)
followed institutional guidelines approved by the local animal review board.
To induce subcutaneous tumors, two groups of six severe combined
immunodeficient mice were injected at one flank with 7  106 cells of two
different SW-620-ADAMTS15–interfered clones (sh clone2 and sh clone12).
As control, the opposite flank in each animal was injected with a stable
clone transfected with the pRS empty vector. Tumor growth was monitored
as described (15). Histopathologic characteristics of the tumors were
evaluated in H&E-stained sections.
Figure 2. ADAMTS15 expression and
localization in HCT-116 cells. A, relative
expression of ADAMTS15 determined by
quantitative reverse transcription-PCR
in a panel of six human colorectal cancer
cell lines. B, detection of recombinant
forms of wild-type ADAMTS15 and
ADAMTS15_G848fs mutant was
determined in HCT-116 lysates and in
conditioned medium using the H-135
antibody. C, immunofluorescence analysis.
The same antibody was employed to
detect both wild-type and mutant
ADAMTS15 in HCT-116. A secondary
FITC-conjugated goat anti-rabbit antibody
was used. Cell nuclei were stained with
Hoechst 33342. Bar , 10 Am.
Cancer Research
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Results
Genetic and epigenetic analysis of ADAMTS15 in human
colorectal cancer. Genomic DNA from a collection of 50 human
colorectal cancer cases and 6 colon cancer cell lines was screened
for mutations through the eight coding exons and intron-exon
junctions of the ADAMTS15 gene. Combining colorectal cancer
samples and cell line data, four heterozygous mutations were
identified, three mutations in patients and one mutation in cell
lines (Fig. 1). All these changes were shown to be somatic by
analysis of DNA from normal tissues of the same individuals. No
correlation between the appearance of mutations and histopath-
ologic features was observed (Supplementary Table S1). In tumors,
one of these changes was a single-base substitution and the other
two were single-base deletions (Fig. 1A). The observed nucleotide
substitution consisted of a cytosine-to-thymine transition at
nucleotide 13777 of the gene (exon 4), resulting in a silent
mutation at codon 504. Hence, the cysteine residue encoded by this
codon remains unaltered in heterozygosis (504Cys>Cys/Cys; Fig. 1A
and B). The remaining changes were nonsynonymous mutations
and consequently may directly affect the ADAMTS15 protein
function. Thus, the coding changes corresponding to deletion
366DG in exon 1 (G122fs; Fig. 1A) would cause a frameshift
generating a truncated protein of 244 amino acids (compared with
950 in the wild-type protein), only containing the signal peptide
and part of the prodomain. In the case of deletion 24544DG
(G849fs; Fig. 1A), it would also produce a frameshift finally leading
to the production of an altered protein of 947 amino acids and
lacking the last two thrombospondin-1 motifs. These deletions
were heterozygously detected in the same tumor sample and may
cause the loss of ADAMTS15 normal function.
Mutational analysis of colorectal cancer cell lines revealed the
presence of one point mutation in DLD-1 cells, consisting of a
single-base substitution 24616C>C/T (874Thr>Thr/Met) in exon
8 (Fig. 1A and B). This change would affect the first of the two
contiguous thrombospondin-1 domains present at the COOH-
terminal region. Interestingly, we also detected a heterozygous
polymorphism in exon 4 (13589T>T/C; 442Tyr>Tyr/His) that had
not been described previously. This single nucleotide polymor-
phism was also detected in two tumor/normal colorectal samples
and in LoVo cells and affects a tyrosine residue that is conserved in
the disintegrin domain of nine different analyzed species (not
shown). We next evaluated the potential effect of the Thr874Met
mutation in metalloprotease function using the Sorting Intolerant
From Tolerant algorithm (22). The normalized probability for a
Thr874Met substitution at the second thrombospondin-1 domain of
ADAMTS15 was <0.01, thus predicting a deleterious effect.
Similarly, the germ-line variant Tyr442His was also predicted to be
deleterious. Overall, these results indicate that, with the exception
of the silent mutation C13777T (Cys504Cys), the functional
relevance of which is uncertain, all remaining mutations found in
this mutational analysis of ADAMTS15 in colon cancer could affect
the normal function of the protein.
Additionally, we examined whether ADAMTS15 could be
epigenetically silenced through methylation. To do this, we first
determined the occurrence of CpG islands in its 5¶ region and
performed a methylation-specific PCR amplification analysis in a
variety of randomly selected colorectal tissue samples. Moreover,
the ADAMTS15 expression pattern in the same samples was
analyzed. No relation between expression levels, normal or tumor
status of the tissues, and promoter methylation was observed
(Supplementary Table S1; Supplementary Fig. S1). Consistent with
these results, ADAMTS15 did not show the expression pattern
characteristic of epigenetically silenced genes (Supplementary
Fig. S1).
Figure 3. ADAMTS15 expression modifies colony-forming ability and invasion properties of HCT-116 colorectal cancer cells. A, average colony formation after 15 days
of selected HCT-116 cells expressing ADAMTS15 and ADAMTS15_G849fs. Bars, SD. ***, P < 0.005, Student’s t test. B, left, expression of ADAMTS15 and
ADAMTS15_G849fs in HCT-116 clones was determined by Western blot analysis; right, HCT-116 cells expressing ADAMTS15 and ADAMTS15_G849fs were plated
in Matrigel invasion chambers and the average number of invasive cells was evaluated. Bars, SD. ***, P < 0.005. Levels of ERK and phospho-ERK (P-ERK ; left) were
evaluated by Western blot of HCT-116 cells expressing ADAMTS15 or ADAMTS15_G849fs. C, morphologic changes induced in HCT-116 ADAMTS15 and
ADAMTS15_G849fs cells. Bar, 40 Am.
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G849fs mutation alters the localization of ADAMTS15. To
examine the functional relevance of the G849fs alteration, we
constructed a vector containing the ADAMTS15 cDNA harboring
this mutation. HCT-116 cells were used for this analysis, as they do
not express ADAMTS15 (Fig. 2A). Western blot analysis using the
H-135 antibody on whole-cell lysates identified specific bands on
extracts from both ADAMTS15 and ADAMTS15_G849fs HCT-116
transfected cells (Fig. 2B). These bands were absent in cells
transfected with an empty vector, indicating that they likely
correspond to the wild-type and mutant forms of ADAMTS15, as
their molecular masses agree well with those predicted for these
proteins, which are very similar in size but distinct at their COOH-
terminal ends (ADAMTS15, f103 kDa; ADAMTS15_G849fs, f102
kDa). However, only the mutant form can be detected in
conditioned medium (Fig. 2B). Moreover, immunostaining of
HCT-116 cells expressing intact ADAMTS15 indicated that the
protease remained attached to the extracellular matrix following
secretion (Fig. 2C). These results suggest that the thrombospondin-
1 units are important to retain the full-length ADAMTS15 protein
attached to the cell surface, because the absence of thrombospon-
din-1 domains as occurs in ADAMTS15_G849fs drives the protein
to the cell medium. Similar results were obtained in 293-EBNA cells
transfected with vectors expressing wild-type and mutant forms of
ADAMTS15 tagged with a FLAG epitope (data not shown), thus
ruling out the possibility that these changes in protease localization
are cell line specific. These data indicate that different forms of
ADAMTS15 may show different cellular localizations, which could
result in the abrogation of the normal function of the protease or in
the acquisition of novel functional properties.
ADAMTS15 expression in colorectal cancer cell lines reduces
colony formation and cell invasion. HCT-116 cells expressing
exogenous ADAMTS15 were selected to examine the ability of
the enzyme to induce antitumor properties. As shown in Fig. 3A ,
ectopic expression of wild-type ADAMTS15 strongly inhibited
colony formation (58.1% colony reduction) compared with control
cells, whereas expression of the ADAMTS15_G849fs form exhibited
a substantially diminished inhibitory effect (38.4% colony reduc-
tion). Similar results were obtained in SW-480 colorectal cells (data
not shown). Following transfection in HCT-116 cells, individual
clones were isolated and screened for ADAMTS15 expression by
quantitative reverse transcription-PCR and Western blot (Fig. 3B,
left ; data not shown). Clones expressing >10-fold ADAMTS15 and
ADAMTS15_G489fs mRNA levels compared with control cells were
selected for further analysis. As shown in Fig. 3B (right), ectopic
expression of ADAMTS15 considerably inhibited invasion of HCT-
116 cells (86.8% reduction). Likewise, the mutant form of the
protein conferred a diminished invasive phenotype to cells (61.6%
reduction; Fig. 3B, right). Altogether, these findings indicate that
Figure 4. ADAMTS15 down-regulation
modifies colony-forming ability and invasion
properties of SW-620 colorectal cancer cells.
A, 293-EBNA cells were cotransfected with the
ADAMTS15 epitope-tagged cDNA construct
(pCEP-ADAMTS15 -FLAG) and a set of four
shRNA interfering plasmids (pRS-shRNA) or with
the control vector (pRS). ADAMTS15 expression
levels were evaluated by Western blot analysis.
B, average colony formation selected
ADAMTS15-interfered SW-620 cells. Bars, SD.
***, P < 0.005, Student’s t test. C, left, ADAMTS15
expression in two interfered SW-620 clones
was determined by Western blot; right,
ADAMTS15-interfered SW-620 cells along with
control cells were plated in Matrigel invasion
chambers, and the average number of invasive
cells was evaluated. Bars, SD. ***, P < 0.005.
Levels of ERK and phospho-ERK (left ) were also
evaluated. D, morphologic changes induced in
ADAMTS15-interfered SW-620 cells versus
control. Bar, 40 Am.
Cancer Research
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overexpression of ADAMTS15 protein in HCT-116 colon cancer
cells results in reduction of both plating efficiency and in vitro
invasive properties, thus reinforcing the proposed role for
ADAMTS15 as a tumor-protective metalloprotease.
Then, and considering that both Xenopus ADAMTS1 (25) and
human ADAMTS12 (15) modulate the Ras-dependent ERK
pathway, we examined the levels of the phosphorylated form of
ERK in HCT-116 cells expressing ectopic ADAMTS15 and
ADAMTS15_G849fs. As shown in Fig. 3B (left), phospho-ERK levels
were very low in cells expressing wild-type ADAMTS15. By contrast,
cells expressing the mutant protein retained the ability to
phosphorylate this kinase, indicating that the COOH-terminal
thrombospondin-1 domains of ADAMTS15 are required for an
effective inhibition of ERK activity. Moreover, a catalytically inactive
ADAMTS15 also confers antitumor properties to HCT-116 (Supple-
mentary Fig. S2), suggesting that these domains are responsible for
its antitumor role. Furthermore, ADAMTS15_G849fs overexpression
induced clear morphologic changes in the invasive HCT-116 cells as
illustrated by the fact that ADAMTS15_G849fs-expressing cells were
larger, flatter, and spindle-shaped in contrast to the smaller and
round-shaped morphology of both control and ADAMTS15-trans-
fected cells (Fig. 3C). Additionally, we observed that neither wild-
type ADAMTS15 nor the mutant-expressing cells showed altered
motility in wound-healing assays (not shown).
Down-regulation of ADAMTS15 by shRNA increases clono-
genicity and invasive properties of colon cancer cells.
According to their significant ADAMTS15 expression levels
(Fig. 2A), SW-620 cells were selected to perform RNA interference
experiments. To do that, four shRNA constructs were employed to
target different regions of ADAMTS15 . First, and to evaluate the
effectiveness of the shRNAs, 293-EBNA cells were transfected either
with the pCEP-ADAMTS15-FLAG and the set of four shRNA
plasmids or with pCEP-ADAMTS15-FLAG and the pRS empty
vector. Western blot analysis revealed that the immunoreactive
signal corresponding to ADAMTS15 was greatly reduced in the
interfered cells when compared with control cells (Fig. 4A). Then,
we examined the functional consequences of knocking down this
protease. To this end, polyclonal populations of SW-620 cells
transfected with the shRNA plasmids were plated along with the
control cells, and their colony-forming ability was tested 15 days
later. Figure 4B shows that ADAMTS15 down-regulation confers an
increased clonogenicity to SW-620 colon cancer cells.
Following puromycin selection, individual clones were expanded
and ADAMTS15 expression levels analyzed by quantitative reverse
transcription-PCR and Western blot (Fig. 4C, left ; data not shown).
Clones 2 and 12 showed a similar reduction in ADAMTS15 mRNA
levels (51.9% and 53.5%, respectively) and were selected to evaluate
their invasive potential using Matrigel-coated invasion chambers.
As shown in Fig. 4C (right), these clones exhibited an enhancement
of their invasive properties compared with cells transfected with
the empty vector (1.4- and 2.6-fold, respectively). Moreover, and
consistent with the above findings in the HCT-116 clones
expressing ADAMTS15 , levels of phospho-ERK were significantly
augmented in both clones (Fig. 4C, left). Furthermore, ADAMTS15
down-regulation also induced morphologic changes, which are
reminiscent of the spindle-shaped phenotype observed previously
in HCT-116 cells expressing mutant ADAMTS15_G849fs (Fig. 4D).
Collectively, these data are also consistent with the proposal that
ADAMTS15 is an antitumor protease.
We next evaluated whether the observed in vitro functional
alterations elicited by ADAMTS15 expression could also be
extended to in vivo models. To this purpose, we examined the
tumorigenic potential of ADAMTS15-depleted cells in subcutane-
ously injected severe combined immunodeficient mice. Consistent
with the above in vitro data, the volume of tumors generated by
ADAMTS15-interfered clones 2 and 12 versus control cells was
significantly augmented over time (Fig. 5A). Histopathologic
analysis revealed a higher percentage of necrotic regions in tumors
derived from both interfered clones when compared with control
tumors (Fig. 5B). Other histologic markers such as angiogenesis or
Figure 5. In vivo subcutaneous tumor growth of SW-620
ADAMTS15-interfered clones. A, severe combined
immunodeficient mice were injected with control SW-620
cells or with the ADAMTS15-interfered clones
(2 or 12). Tumor growth was followed during 8 wk
postinjection. Bars, SD. *, P < 0.05; ***, P < 0.005,
Student’s t test. B, representative H&E staining of
formalin/paraffin-embedded tumors obtained after 8 wk of
subcutaneous growth (20). Asterisk, necrotic
tumor region.
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local invasion showed no remarkable differences among the
different tumors. In all cases, tumors were classified as poorly
differentiated adenocarcinomas (Fig. 5B ; data not shown).
Collectively, these results support the conclusion that ADAMTS15
exhibits an in vivo antitumorigenic effect.
ADAMTS15 expression negatively correlates with the histo-
pathologic differentiation grade in colon adenocarcinoma. To
further evaluate the putative clinical relevance of ADAMTS15
expression in colon cancer, we performed an immunohistochem-
ical analysis of two tissue arrays containing normal and tumor
colorectal specimens (Fig. 6). ADAMTS15 was detected in normal
samples, preferentially in the apical side of the colon mucosa.
However, in most analyzed samples, ADAMTS15 expression was
reduced in the tumor tissue in comparison with the corresponding
normal epithelia. Moreover, ADAMTS15 immunostaining inversely
correlated with the histopathologic grade of colorectal tumors
(Fig. 6). Thus, we evaluated ADAMTS15 expression levels in 77
areas ranging from adenomatous polyps to different grades of
colon adenocarcinoma. Immunoreactivity was scored as shown in
Supplementary Table S2. The intensity of immunostaining in
adenomatous polyps varied among samples: 25% of areas with an
intense staining, 37.5% with a slight staining, and the remaining
37.5% areas with negative staining. A direct correlation between
ADAMTS15 down-regulation and tumor development was assessed
by the observation that positive ADAMTS15 staining was found in
58.3% of well-differentiated tumors, 21% of moderately differenti-
ated tumors, and 0% of poorly differentiated colorectal carcinomas.
These data suggest that ADAMTS15 could represent an effective
differentiation marker for the histopathologic grading of colonic
adenocarcinoma.
Discussion
In this work, we provide functional evidence that ADAMTS15 is a
new enzyme in the growing category of tumor-defying proteases
(7). The gene encoding this metalloprotease was originally cloned
in our laboratory as part of our long-term studies aimed at
identification of proteases associated with tumor progression (23).
However, its precise physiologic and pathologic relevance is
currently unknown. The first indication regarding a potential
protective role for ADAMTS15 derived from the observation that
low ADAMTS15 expression levels coupled to high ADAMTS8 levels
conferred poor prognosis to breast cancer patients (19). Moreover,
ADAMTS15 was identified as one of the so-called CAN genes found
to be mutated in a small set of colorectal cancers (20). To provide
functional support to the putative relevance of ADAMTS15 as a
tumor suppressor protease, we extended the mutational analysis of
this metalloprotease gene to a panel of 50 colorectal cancers and
6 colon cancer cell lines. This work allowed us to identify four
new mutations, validating the proposal that ADAMTS15 is mutated
in human colon carcinomas. Next, we performed different
functional approaches aimed at evaluating the antitumorigenic
properties of ADAMTS15 using cellular models. As a first step to
this purpose, we proceeded to exogenously express ADAMTS15 in
HCT-116 cells, which led to a considerable reduction in both colony
formation and invasive capacities of this cell line. Moreover,
functional analysis of selected ADAMTS15-knockdown SW-620
clones showed an enhancement of their invasive capacities and
growing ability when compared with control clones. These data
provide the first functional evidence on the tumor suppressor
properties of ADAMTS15.
Furthermore, we could observe in these colon cancer cell lines
that defective or tumor-derived mutant ADAMTS15 invasive clones
exhibited morphologic alterations characteristic of cells that have
lost their epithelial features and acquired a mesenchymal
phenotype. Epithelial-to-mesenchymal transition is a characteristic
feature of cells undergoing invasion, which is an essential step for
transformed cells to progress and metastasize in distant organs
(26). In agreement with these data, we also found that the Ras/
mitogen-activated protein kinase oncogenic pathway, known to
induce epithelial-to-mesenchymal transition events, is modulated
by ADAMTS15. Thus, we observed a marked inhibition of ERK
phosphorylation in ADAMTS15-expressing HCT-116 clones and an
activation in the ADAMTS15 knockdown SW-620 clones. Previous
studies have shown that sustained activation of Ras/mitogen-
activated protein kinase pathway is involved in promoting cellular
processes associated with tumor progression (27). The presence of
thrombospondin-1 domains in ADAMTS15 could be responsible for
switching off this pathway. In fact, ectopic expression of
thrombospondin-1 markedly inhibits tumor formation (28).
Moreover, expression of thrombospondin-1 is up-regulated by the
tumor suppressor gene p53 and down-regulated by oncogenes such
as Myc and Ras (29). Furthermore, it has been reported that both
Xenopus ADAMTS1 and human ADAMTS12 can also inhibit this
pathway (15, 25). These two ADAMTS undergo proteolytic
processing events to generate fragments with prometastatic or
antimetastatic activities depending on the presence of thrombo-
spondin-1 domains in them (15, 30, 31). In fact, it has been proven
Figure 6. ADAMTS15 expression inversely correlates with histopathologic
differentiation grade in human colorectal carcinomas. Human colorectal tissue
arrays were immunostained for ADAMTS15 and four representative tissue
sections are shown. ADAMTS15 shows positive immunostaining in luminal
epithelia of normal mucosa (NM ). Adenomatous polyp (AP ) also shows strong
immunoreactivity to ADAMTS15. Well-differentiated adenocarcinoma (WD)
still presents significant expression. Poorly differentiated high-grade
adenocarcinoma (PD ) does not show staining for the metalloprotease.
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that these domains confer angio-inhibitory properties to different
ADAMTS (13) and may be involved in the modulation of the ERK
signaling pathway (15, 25). Interestingly, the 24544DG mutation
identified in our ADAMTS15 mutational analysis would result in an
enzyme lacking the last two thrombospondin-1 domains. We have
engineered an ADAMTS15 isoform mimicking this situation, which
shows reduced invasive properties compared with the full-length
protein. Moreover, cells expressing this form displayed higher levels
of phosphorylated ERK than those detected in cells expressing
intact ADAMTS15. These data would indicate that the thrombo-
spondin motifs are essential for ADAMTS15 to act as a tumor
suppressor protease. Furthermore, we have also found that the
presence of these domains is important to immobilize the protease
in the pericellular space following its secretion, which would
facilitate a putative interaction of the thrombospondin-1 domains
with their receptors as a mechanism to inhibit ERK activation (25).
In contrast, the form lacking these domains is secreted to the cell
medium, thus hindering this putative ERK-inhibitory function.
Consistent with the above data, in vivo experiments based on
subcutaneous injection of the interfered clones in severe combined
immunodeficient mice revealed that ADAMTS15 knockdown
markedly promotes in vivo tumor growth. Additionally, we carried
out an immunohistochemical analysis of ADAMTS15 in colorectal
tissue samples with the finding that this metalloprotease is
preferentially detected at the apical side of the colonic normal
mucosa, whereas its presence shows a clear decay within the tumor
tissue. Interestingly, the negative correlation between ADAMTS15
expression and the differentiation status of the colorectal tumors
agrees with the suggested protective properties of ADAMTS15 in
tumors of colorectal origin.
We have also examined whether ADAMTS15 can be an
epigenetically silenced gene in colon cancer, a quite common
mechanism to inactivate several tumor suppressor genes in
colorectal carcinomas (32). Moreover, ADAMTS1 and ADAMTS18
have been found to be hypermethylated in these malignancies
(16, 18). However, our results revealed that this is not the case for
ADAMTS15 because an analysis of paired normal/tumor samples
and cDNAs from colon carcinomas did not show the expected
expression pattern for epigenetically silenced genes. Thus, genetic
mutations rather than epigenetic silencing seem to be the
mechanism that contributes to ADAMTS15 inactivation in some
cases of human colorectal carcinomas. The total number of
identified mutations in the ADAMTS15 gene is relatively low but
similar to that found in other genes reported as novel targets of
genetic inactivation in cancer (20, 21, 33). Nevertheless, it is very
interesting that mutation events may result in the inactivation of
this protease gene in other human malignant tumors as assessed
by the recent findings showing that ADAMTS15 is mutated in
pancreatic (33) and lung cancers,5 although no functional analysis
of these mutations has been reported yet. Additionally, it is also
noteworthy that ADAMTS15 gene is located in chromosome
11q24.3 between markers D11S912 and D11S969 , a region of
frequent loss of heterozygosity in different tumors including
colorectal cancer (34). This fact would provide a new clue on the
potential relationship between loss-of-function of ADAMTS15 and
development of colorectal cancer.
In summary, the results presented in this work provide strong
support to the proposal that ADAMTS15 is a metalloprotease with
tumor-protective functions. This finding, together with previous
observations on the antitumorigenic properties of different
proteases (7), emphasizes the need to more precisely characterize
the cancer degradome (35). These approaches will contribute to
identify those proteolytic enzymes that constitute appropriate
therapeutic targets and to distinguish them from those that confer
tumor protection. Ultimately, the structural and functional discrim-
ination between protease targets and antitargets in cancer will be
very helpful to design new inhibitors aimed to specifically block the
unwanted proteolytic activities associated with tumor progression.
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